RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
RECURSION PHARMACEUTICALS, INC. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 3.5%
- Operating margin
- -991.7%
- Net margin
- -945.9%
- Return on equity, FY2025
- -59.5%
Financial strength
- Current ratio
- 5.03
- Debt to equity
- 0.02
- Debt to assets
- 1.2%
- Cash to current liabilities
- 455.2%
Valuation
- P/E ratio
- –
- Price to sales
- 35.04
- Price to book
- 2.10
- Dividend yield
- –